title: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.
authors.forename: Omer
authors.initials: O
authors.lastname: Dizdar
authors.forename: Didem S
authors.initials: DS
authors.lastname: Dede
authors.forename: Nilufer
authors.initials: N
authors.lastname: Bulut
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D045744:Cell Line, Tumor; D000069439:Dasatinib; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D066246:ErbB Receptors / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D000069439:Dasatinib